FEMASYS INC. 10-Q Summary: Q1 2025
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended March 31, 2025. Femasys Inc. is a biomedical innovator focused on women's health, specifically infertility and permanent birth control. The company operates as a single segment entity developing therapeutic and diagnostic products. Key products include FemaSeed (intratubal insemination), FemVue (diagnostic), and the product candidate FemBloc (non-surgical permanent birth control). In March 2025, the company announced CE mark certification for the FemBloc delivery system in Europe and strategic distribution partnerships in Spain.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Sales | $341,264 | $271,140 |
| Net Loss | $(5,896,839) | $(3,599,510) |
| Net Loss Per Share (Basic & Diluted) | $(0.23) | $(0.17) |
| Cash and Cash Equivalents (End of Period) | $3,820,208 | $17,835,968 |
| Convertible Notes Payable (Net) | $5,762,927 | $5,406,228 |
| Accumulated Deficit | $(133,095,096) | $(111,981,139) |
| Operating Cash Flow | $(4,765,214) | $(4,568,124) |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased by 25.9% ($70,124) primarily due to increased sales of FemaSeed.
- Expense Increases:
- R&D Expenses: Increased 67.6% to $2.97M, driven by higher regulatory costs, material/development costs, and compensation.
- Sales & Marketing: Increased 202.4% to $908,567 due to the recruitment of a commercial team.
- Interest Expense: Increased 27.1% to $459,449, largely due to non-cash amortization of debt discounts.
- Liquidity Position: Cash balances decreased significantly year-over-year (from ~$17.8M to ~$3.8M) despite a net cash inflow of $368,447 in Q1 2025. This inflow was driven by $5.23M in financing proceeds from at-the-market stock sales, which offset operating cash burn.
- Inventory Build: Inventory increased by $815,865 to $3.86M, reflecting preparation for commercialization.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for at least one year from the issuance of these statements. Current cash is expected to fund operations only into the early third quarter of 2025.
- Financing Needs: The company anticipates needing additional capital to fund the pivotal clinical trial for FemBloc, commercialization efforts, and ongoing operations. There is no assurance that financing will be available on acceptable terms.
- Debt Obligations: Convertible notes totaling $6.85M principal mature in November 2025. The company must either convert these notes or secure funds to repay them.
- Regulatory Milestones: The company is awaiting final EMA review for the FemBloc blended polymer (expected mid-2025) and is enrolling participants in the U.S. pivotal trial (NCT05977751).
- Risk Factors: Risks include potential FDA disruptions due to government funding shortages, failure to secure additional financing, and the volatility of the common stock price.
Investor Verification Checklist
- Verify the timeline and sufficiency of the at-the-market (ATM) equity facility (approx. $1.6M remaining) to bridge the funding gap until Q3 2025.
- Confirm the status of the November 2025 convertible note maturity and the company's plan for conversion or repayment.
- Monitor the progress of the FemBloc pivotal clinical trial enrollment and the final EMA approval status for the blended polymer.
- Assess the burn rate relative to the $3.82M cash balance and the impact of the recent inventory build on working capital.
- Review the share-based compensation expense ($367k in Q1) and the remaining unrecognized expense ($2.03M) for future dilution impact.